Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of an extended-spectrum penicillin (piperacillin) and a beta-lactamase inhibitor (tazobactam). It is active against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
## Adult Dosing
The typical dose is 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) every 6 hours or 4.5 grams (piperacillin 4 g / tazobactam 0.5 g) every 6 or 8 hours intravenously. Dosing frequency and duration depend on the type and severity of infection, and the pathogen's susceptibility.
## Pediatric Dosing
* **Infants and Children (2 months to 12 years):** Dosing is typically based on the piperacillin component, ranging from 80 mg/kg/dose to 100 mg/kg/dose, administered every 6 or 8 hours. The maximum dose should not exceed the adult dose. Tazobactam is dosed at a 1:8 ratio to piperacillin. Consult specific pediatric guidelines for precise dosing based on weight and indication.
* **Neonates:** Use is generally not recommended due to limited data and potential for kernicterus.
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No adjustment needed.
* CrCl 20-40 mL/min: Administer usual dose every 8 hours.
* CrCl < 20 mL/min: Administer usual dose every 12 hours.
* Consider hemodialysis: Administer usual dose every 12 hours and supplement with one-third of the usual dose after each dialysis session.
## Contraindications
* Known severe hypersensitivity to piperacillin, tazobactam, other beta-lactam antibiotics, or any component of the formulation.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, and phlebitis at the injection site. Serious adverse effects include Clostridioides difficile-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, and hematologic abnormalities (e.g., neutropenia, thrombocytopenia).
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin-tazobactam plasma concentrations.
* **Neuromuscular blocking agents:** Piperacillin may prolong the action of rocuronium.
* **Warfarin:** Piperacillin may decrease serum concentrations of warfarin, potentially reducing its anticoagulant effect. Monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance, increasing toxicity.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for signs and symptoms of C. difficile infection.
* Monitor renal function, liver function, and complete blood counts, especially with prolonged therapy or in patients with renal impairment.
* Monitor prothrombin time/INR if used concurrently with warfarin.
## Clinical Pearls
* Piperacillin-tazobactam has a broad spectrum of activity, including many nosocomial pathogens.
* It is crucial to reconstitute and dilute the drug appropriately as per manufacturer instructions, as it is administered intravenously.
* Duration of therapy is typically 7-14 days, but should be tailored to the patient's clinical response.
* Given its broad spectrum, de-escalation of therapy may be appropriate once culture and susceptibility results are available.
***
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for definitive patient care decisions.
